No Data
ZAI LAB (09688.HK) plans to hold a Board of Directors meeting on May 8 to approve the first-quarter performance.
Gelonghui reported on April 24 that ZAI LAB (09688.HK) announced that the Board of Directors' Audit Committee will review and approve on May 8, 2025 (Thursday) the company's and its subsidiaries' unaudited quarterly performance for the three months ending March 31, 2025, prepared in accordance with US Generally Accepted Accounting Principles and applicable rules of the USA Securities and Exchange Commission ("first quarter performance") and its release.
ZAI LAB: NOTICE OF AUDIT COMMITTEE ACTION AND DATE OF PUBLICATION OF FIRST QUARTER 2025 RESULTS ANNOUNCEMENT
Zai Lab To Present Data From Phase 1 Trial Of DLL3-Targeted Antibody-Drug Conjugate ZL-1310 At 2025 ASCO Annual Meeting
Asian Equities Traded in the US as American Depositary Receipts Surge in Tuesday Trading
ZAI LAB (09688) issued 2 million new shares on April 22.
ZAI LAB (09688) announced that on April 22, 2025, it will execute in accordance with the previously disclosed terms (1)...
Hong Kong stocks movement | ZAI LAB (09688) rises over 7% as the application for the new indication of Ripretinib has been accepted.
ZAI LAB (09688) rose over 7%, as of the time of writing, it increased by 7.02%, priced at 24.4 Hong Kong dollars, with a transaction amount of 0.279 billion Hong Kong dollars.
